Leveraging premalignant biology for immune-based cancer prevention

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 39, 2016, Pages 10750-10758

  Spira, Avrum ^a   Disis, Mary L ^b   Schiller, John T ^c   Vilar, Eduardo ^d   Rebbeck, Timothy R ^e   Bejar, Rafael ^f   Ideker, Trey ^f   Arts, Janine ^g   Yurgelun, Matthew B ^h   Mesirov, Jill P ^f   Rao, Anjana ⁱ   Garber, Judy ^h   Jaffee, Elizabeth M ^j   Lippman, Scott M ^f  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g JOHNSON AND JOHNSON   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

Biology; Cancer prevention; Immune oncology; Premalignancy; Vaccines

Indexed keywords

APOBEC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CANCER VACCINE; PROTEIN; UNCLASSIFIED DRUG; TUMOR PROTEIN;

CANCER IMMUNIZATION; CANCER MODEL; CANCER PREVENTION; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONFERENCE PAPER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; NONHUMAN; PRECANCER; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; BIOLOGICAL MODEL; GERM CELL; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY;

GERM CELLS; HUMANS; IMMUNE SYSTEM; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; PRECANCEROUS CONDITIONS; TUMOR MICROENVIRONMENT;

EID: 84989881120     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1608077113     Document Type: Article

References (147)

1. Vogelstein B, et al. (2013) Cancer genome landscapes. Science 339(6127):1546-1558.
2. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
3. Hoadley KA, et al.; Cancer Genome Atlas Research Network (2014) Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158(4):929-944.
4. Abba MC, et al. (2015) A molecular portrait of high-grade ductal carcinoma in situ. Cancer Res 75(18):3980-3990.
5. William WN, Jr, et al. (2016) Erlotinib and the risk of oral cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol 2(2):209-216.
6. Garrett WS (2015) Cancer and the microbiota. Science 348(6230):80-86.
7. Heath JR, Ribas A, Mischel PS (2016) Single-cell analysis tools for drug discovery and development. Nat Rev Drug Discov 15(3):204-216.
8. Stadler ZK, et al. (2016) Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels. J Clin Oncol 34(18):2141-2147.
9. Vogelstein B, et al. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319(9):525-532.
10. Nikolaev SI, et al. (2012) A single-nucleotide substitution mutator phenotype revealed by exome sequencing of human colon adenomas. Cancer Res 72(23):6279-6289.
11. Sottoriva A, et al. (2015) A Big Bang model of human colorectal tumor growth. Nat Genet 47(3):209-216.
12. Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407):330-337.
13. Lawrence MS, et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499(7457):214-218.
14. Zhang B, et al.; NCI CPTAC (2014) Proteogenomic characterization of human colon and rectal cancer. Nature 513(7518):382-387.
15. Drost J, et al. (2015) Sequential cancer mutations in cultured human intestinal stem cells. Nature 521(7550):43-47.
16. Stachler MD, et al. (2015) Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet 47(9):1047-1055.
17. Sakr RA, et al. (2016) Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships. Mol Oncol 10(2):360-370.
18. McDaniel AS, et al. (2015) Next-generation sequencing of tubal intraepithelial carcinomas. JAMA Oncol 1(8):1128-1132.
19. Murphy SJ, et al. (2013) Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology 145(5):1098-1109.
20. Walker BA, et al. (2014) Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28(2):384-390.
21. Barrio S, et al. (July 29, 2016) Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome. Leukemia, 10.1038/leu.2016.172.
22. Jasperson KW, Tuohy TM, Neklason DW, Burt RW (2010) Hereditary and familial colon cancer. Gastroenterology 138(6):2044-2058.
23. Borras E, et al. (2016) Genomic landscape of colorectal mucosa and adenomas. Cancer Prev Res (Phila) 9(6):417-427.
24. Rashid M, et al. (2016) Adenoma development in familial adenomatous polyposis and MUTYH-associated polyposis: Somatic landscape and driver genes. J Pathol 238(1):98-108.
25. Samadder NJ, et al. (2016) Effect of Sulindac and Erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: A randomized clinical trial. JAMA 315(12):1266-1275.
26. Vilar E, Tabernero J (2013) Molecular dissection of microsatellite instable colorectal cancer. Cancer Discov 3(5):502-511.
27. Swanton C, McGranahan N, Starrett GJ, Harris RS (2015) APOBEC enzymes: Mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov 5(7):704-712.
28. Albuquerque C, et al. (2002) The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum Mol Genet 11(13):1549-1560.
29. Knudsen AL, Bisgaard ML, Bulow S (2003) Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2(1):43-55.
30. Laken SJ, et al. (1997) Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 17(1):79-83.
31. Micol JB, Abdel-Wahab O (2014) Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations. Haematologica 99(2):201-203.
32. Churpek JE, et al. (2015) Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood 126(22):2484-2490.
33. Kilpivaara O,et al. (2009)Agermline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41(4):455-459.
34. Pietra D, et al. (2012) JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. Am J Hematol 87(7):746-747.
35. Lu C, et al. (2015) Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun 6:10086.
36. Oxnard GR, et al. (2012) Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol 7(6):1049-1052.
37. Jaiswal S, et al. (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371(26):2488-2498.
38. Xie M, et al. (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20(12):1472-1478.
39. Kwok B, et al. (2015) MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood 126(21):2355-2361.
40. Steensma DP, et al. (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126(1):9-16.
41. Shalapour S, Karin M (2015) Immunity, inflammation, and cancer: An eternal fight between good and evil. J Clin Invest 125(9):3347-3355.
42. Kaneda MM, et al. (May 13, 2016) Macrophage PI3Kã drives pancreatic ductal adenocarcinoma progression. Cancer Discov 6(8):870-885.
43. West NR, McCuaig S, Franchini F, Powrie F (2015) Emerging cytokine networks in colorectal cancer. Nat Rev Immunol 15(10):615-629.
44. Le DT, et al. (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509-2520.
45. Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 27(4):450-461.
46. Bailey HH, et al. (2016) American Society of Clinical Oncology Statement: Human papillomavirus vaccination for cancer prevention. JClinOncol34(15):1803-1812.
47. Trimble CL (2014) HPV infection-associated cancers: Next-generation technology for diagnosis and treatment. Cancer Immunol Res 2(10):937-942.
48. Chan K, et al. (2015) An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet 47(9):1067-1072.
49. den Boon JA, et al. (2015) Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling. Proc Natl Acad Sci USA 112(25):E3255-E3264.
50. Kataoka K, et al. (2016) Aberrant PD-L1 expression through 3?-UTR disruption in multiple cancers. Nature 534(7607):402-406.
51. DuPage M, Jacks T (2013) Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr Opin Immunol 25(2):192-199.
52. Teng MW, Galon J, Fridman WH, Smyth MJ (2015) From mice to humans: Developments in cancer immunoediting. J Clin Invest 125(9):3338-3346.
53. Shankaran V, et al. (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832):1107-1111.
54. Salavoura K, Kolialexi A, Tsangaris G, Mavrou A (2008) Development of cancer in patients with primary immunodeficiencies. Anticancer Res 28(2B):1263-1269.
55. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 370(9581):59-67.
56. Finn OJ, Beatty PL (2016) Cancer immunoprevention. Curr Opin Immunol 39:52-58.
57. Nardy AF, Freire-de-Lima L, Freire-de-Lima CG, Morrot A (2016) The sweet side of immune evasion: Role of glycans in the mechanisms of cancer progression. Front Oncol 6:54.
58. Segal NH, et al. (2008) Epitope landscape in breast and colorectal cancer. Cancer Res 68(3):889-892.
59. Castle JC, et al. (2012) Exploiting the mutanome for tumor vaccination. Cancer Res 72(5):1081-1091.
60. Yadav M, et al. (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515(7528):572-576.
61. Giannakis M, et al. (2016) Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Reports 15:1-9.
62. Phan VT, et al. (2013) Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci USA 110(15):6079-6084.
63. Roghanian A, Fraser C, Kleyman M, Chen J (2016) B cells promote pancreatic tumorigenesis. Cancer Discov 6(3):230-232.
64. Keenan BP, et al. (2014) A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology 146(7):1784-1794.
65. Blaschke K, et al. (2013) Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 500(7461):222-226.
66. Incio J, et al. (2015) Metformin reduces desmoplasia in pancreatic cancer by reprogramming stellate cells and tumor-associated macrophages. PLoS One 10(12):e0141392.
67. Eikawa S, et al. (2015) Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA 112(6):1809-1814.
68. Pearce EL, et al. (2009) Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460(7251):103-107.
69. Thompson E, et al. (2016) The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol 29(3):249-258.
70. Schneider RK, et al. (2016) Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med 22(3):288-297.
71. Raaijmakers MH, et al. (2010) Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464(7290):852-857.
72. Fridman WH, Pagès F, Sautès-Fridman C, Galon J (2012) The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 12(4):298-306.
73. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL (2011) The immune hallmarks of cancer. Cancer Immunol Immunother 60(3):319-326.
74. Lutz M, et al. (2015) Boost and loss of immune responses against tumor-associated antigens in the course of pregnancy as a model for allogeneic immunotherapy. Blood 125(2):261-272.
75. Domchek SM, et al. (2007) Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res 67(21):10546-10555.
76. Dhodapkar MV, et al. (2015) Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood 126(22):2475-2478.
77. Grivennikov SI, et al. (2012) Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491(7423):254-258.
78. Gur C, et al. (2015) Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42(2):344-55.
79. Feng Q, et al. (2015) Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun 6:6528.
80. Belcheva A, et al. (2014) Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. Cell 158(2):288-299.
81. Levy J, et al. (2015) Intestinal inhibition of Atg7 prevents tumour initiation through a microbiome-influenced immune response and suppresses tumour growth. Nat Cell Biol 17(8):1062-1073.
82. Yang JY, et al. (2016) Enteric viruses ameliorate gut inflammation via toll-like receptor 3 and toll-like receptor 7-mediated interferon-B production. Immunity 44(4):889-900.
83. Saeterdal I, et al. (2001) Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci USA 98(23):13255-13260.
84. Garbe Y, Maletzki C, Linnebacher M (2011) An MSI tumor specific frameshift mutation in a coding microsatellite of MSH3 encodes for HLA-A0201-restricted CD8+ cytotoxic T cell epitopes. PLoS One 6(11):e26517.
85. Schwitalle Y, et al. (2008) Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134(4):988-997.
86. Staffa L, et al. (2015) Mismatch repair-deficient crypt foci in Lynch syndrome-molecular alterations and association with clinical parameters. PLoS One 10(3): e0121980.
87. Yurgelun MB, et al. (2012) Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) 5(4): 574-582.
88. Kloor M, et al. (2007) Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer 121(2):454-458.
89. Echterdiek F, et al. (2015) Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. OncoImmunology 5(2):e1075692.
90. Shlien A, et al.; Biallelic Mismatch Repair Deficiency Consortium (2015) Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet 47(3):257-262.
91. Aronson M, et al. (2016) Gastrointestinal findings in the largest series of patients with hereditary biallelic mismatch repair deficiency syndrome: Report from the International Consortium. Am J Gastroenterol 111(2):275-284.
92. Bouffet E, et al. (2016) Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34(19):2206-2211.
93. Yurgelun MB, et al. (2015) Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. Gastroenterology 149(3):604-613.
94. Nik-Zainal S, et al. (2016) Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534(7605):47-54.
95. Decker B, et al. (2016) Biallelic BRCA2 mutations shape the somatic mutational landscape of aggressive prostate tumors. Am J Hum Genet 98(5):818-829.
96. Strickland KC, et al. (2016) Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 7(12):13587-13598.
97. George SH, Milea A, Shaw PA (2012) Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status. Clin Cancer Res 18(22): 6199-6207.
98. Sedic M, et al. (2015) Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nat Commun 6:7505.
99. Lim E, et al. (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15(8): 907-913.
100. To C, et al. (2014) The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res (Phila) 7(7):698-707.
101. Nolan E, et al. (2016) RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med 22(8):933-939.
102. Sigl V, et al. (2016) RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell Res 26(7):761-774.
103. Knisbacher BA, Gerber D, Levanon EY (2016) DNA editing by APOBECs: A genomic preserver and transformer. Trends Genet 32(1):16-28.
104. Leonard B, et al. (2015) The PKC/NF-êB signaling pathway induces APOBEC3B expression in multiple human cancers. Cancer Res 75(21):4538-4547.
105. Nik-Zainal S, et al. (2014) Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet 46(5):487-491.
106. Wen WX, et al. (2016) Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation. Breast Cancer Res 18(1):56.
107. Zhang T, et al. (2013) Evidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinoma. Hum Mol Genet 22(6):1262-1269.
108. Cescon DW, Haibe-Kains B, Mak TW (2015) APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci USA 112(9):2841-2846.
109. Caval V, Suspène R, Shapira M, Vartanian JP, Wain-Hobson S (2014) A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage. Nat Commun 5:5129.
110. O'Connell MA, Mannion NM, Keegan LP (2015) The epitranscriptome and innate immunity. PLoS Genet 11(12):e1005687.
111. Kidd JM, Newman TL, Tuzun E, Kaul R, Eichler EE (2007) Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet 3(4):e63.
112. Lu Y, et al. (2014) Most common 'sporadic' cancers have a significant germline genetic component. Hum Mol Genet 23(22):6112-6118.
113. Nan H, et al. (2015) Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA 313(11):1133-1142.
114. Petridis C, et al. (2016) Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Res 18(1):22.
115. Lowy DR, Collins FS (2016) Aiming high-Changing the trajectory for cancer. N Engl J Med 374(20):1901-1904.
116. Giordano TJ (2014) The cancer genome atlas research network: A sight to behold. Endocr Pathol 25(4):362-365.
117. Weinstein JN, et al.; Cancer Genome Atlas Research Network (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45(10):1113-1120.
118. Dang L, et al. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462(7274):739-744.
119. Losman JA, et al. (2013) (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339(6127):1621-1625.
120. Ortmann CA, et al. (2015) Effect of mutation order on myeloproliferative neoplasms. N Engl J Med 372(7):601-612.
121. Zhou J, et al. (2014) One-step generation of different immunodeficient mice with multiple gene modifications by CRISPR/Cas9 mediated genome engineering. Int J Biochem Cell Biol 46:49-55.
122. Zumwalde NA, et al. (2016) Analysis of immune cells from human mammary ductal epithelial organoids reveals Vdelta2+ T cells that efficiently target breast carcinoma cells in the presence of bisphosphonate. Cancer Prev Res (Phila) 9(4):305-316.
123. Kaufman CK, et al. (2016) A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science 351(6272):aad2197.
124. Kato S, Lippman SM, Flaherty KT, Kurzrock R. (2016) The conundrum of genetic "drivers" in benign conditions. J Natl Cancer Inst, 108(8).pii:djw036.
125. Zaretsky JM, et al. (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 37(9):819-829.
126. Rashidian M, et al. (2015) Noninvasive imaging of immune responses. Proc Natl Acad Sci USA 112(19):6146-6151.
127. Wellbrock C. (2016) Melanoma and the microenvironment-age matters. N Engl J Med 375(7):696-698.
128. Lucia A, Ramirez M. (2016) Muscling in on cancer. N Engl J Med 375(9):892-894.
129. Tewari KS, et al. (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370(8):734-743.
130. Everett JN, et al. (2014) Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm. JAMA Dermatol 150(12):1315-1321.
131. Dudley JC, Lin MT, Le DT, Eshleman JR (2016) Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 22(4):813-820.
132. Syngal S, et al.; American College of Gastroenterology (2015) ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110(2):223-262, quiz 263.
133. Newcomb PA, et al.; Colon Cancer Family Registry (2007) Colon Cancer Family Registry: An international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev 16(11):2331-2343.
134. Beatty PL, et al. (2016) Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas. Cancer Immunol Immunother 65(7):771-778.
135. Vasen H, et al. (2016) Benefit of surveillance for pancreatic cancer in high-risk individuals: Outcome of long-term prospective follow-up studies from three European expert centers. J Clin Oncol 34(17):2010-2019.
136. Milne RL, Antoniou A. (2016) Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. Endocr Relat Cancer. pii:ERC-16-0277.
137. Wong TN, et al. (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518(7540):552-555.
138. Di Stasi A, Jimenez AM, Minagawa K, Al-Obaidi M, Rezvani K (2015) Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol 6:36.
139. Solomon BM, et al. (2016) Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. Leukemia 20(2):331-336.
140. Mesri EA, Feitelson MA, Munger K (2014) Human viral oncogenesis: A cancer hallmarks analysis. Cell Host Microbe 15(3):266-282.
141. Romero P, et al. (2016) The human vaccines project: A roadmap for cancer vaccine development. Sci Transl Med 8(334):334ps9.
142. Imperiale TF, Ransohoff DF, Itzkowitz SH (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370:1287-1297.
143. Nair S, et al. (2016) Clonal immunoglobulin against lysolipids in the origin of myeloma. N Engl J Med 374(6):555-561.
144. Silvestri GA, et al.; AEGIS Study Team (2015) A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med 373(3):243-251.
145. Im JS, et al. (2016) Immune-modulation by epidermal growth factor receptor inhibitors: implication on anti-tumor immunity in lung cancer. PLoS One 11(7):e0160004.
146. Corriden R, et al. (2015) Tamoxifen augments the innate immune function of neutrophils through modulation of intracellular ceramide. Nat Commun 13;6:8369.
147. Forslund K, et al. (2015) Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528(7581):262-266.